Since low levels of cN-II were associated with a poor prognosis in NSCLC patients receiving gemcitabine and with a better prognosis in AML patients receiving sytrabine (Seve et al, 2005), further studies are necessary to confirm the usefulness of cN-II as a prognosis factor. The gene discussed is NT5C2; the disease is non-small cell lung carcinoma.